Stock Events

Stock Events

Grace Therapeutics 

€0
131
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

23JunExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.36
-0.21
-0.06
0.09
Expected EPS
-0.2126355
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-11.87MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow L8S.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Amarin
AMRN
Mkt Cap338.71M
Amarin Corporation plc focuses on the development and commercialization of therapeutics for cardiovascular health, directly competing with Acasti Pharma's focus on omega-3 phospholipids for similar conditions.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC, a large pharmaceutical company, has a diverse portfolio that includes treatments for cardiovascular diseases, competing with Acasti Pharma's cardiovascular focus.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad range of products including treatments for cardiovascular diseases, making it a competitor to Acasti Pharma in the cardiovascular therapeutic area.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. offers a wide range of healthcare solutions, including cardiovascular disease treatments, competing with Acasti Pharma's product offerings.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, with its extensive research and development in cardiovascular diseases, competes with Acasti Pharma in the market for cardiovascular health solutions.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc has a diversified portfolio that includes cardiovascular drugs, making it a competitor to Acasti Pharma in the cardiovascular space.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including those for cardiovascular diseases, competing with Acasti Pharma.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. focuses on human therapeutics, including cardiovascular disease treatments, which positions it as a competitor to Acasti Pharma.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company offers a wide range of prescription pharmaceuticals in several therapeutic areas, including cardiovascular diseases, competing with Acasti Pharma's focus.

About

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Show more...
CEO
Country
US
ISIN
US00439U1043
WKN
000A40LEL

Listings

F
DE
A1P0.F
XNAS
US
GRCE
F
DE
L8S.F
BOATS
BOATS
GRCE.BOATS

0 Comments

Share your thoughts

FAQ

What is Grace Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Grace Therapeutics stocks are traded under the ticker L8S.F.
When is the next Grace Therapeutics earnings date?▼
Grace Therapeutics is going to release the next earnings report on June 23, 2026.
What were Grace Therapeutics earnings last quarter?▼
L8S.F earnings for the last quarter are -0.12 EUR per share, whereas the estimation was -0.24 EUR resulting in a +50% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Grace Therapeutics revenue for the last year?▼
Grace Therapeutics revenue for the last year amounts to 0 EUR.
What is Grace Therapeutics net income for the last year?▼
L8S.F net income for the last year is -11.87M EUR.
In which sector is Grace Therapeutics located?▼
Grace Therapeutics operates in the Materials sector.
When did Grace Therapeutics complete a stock split?▼
The last stock split for Grace Therapeutics was on July 10, 2023 with a ratio of 1:6.